SIREN : 440110088
LABORATOIRE UNITHER is a French company founded 24 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in AMIENS (80080), this company of category ETI shows in 2024 a revenue of 287.9 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 287 947 277 € | 238 826 274 € | 199 725 575 € | 152 278 058 € | 185 101 218 € | 188 882 429 € | 162 095 874 € | 114 220 490 € | 35 454 743 € | 141 210 597 € |
| Net income | 72 633 389 € | 52 715 587 € | 40 808 926 € | 25 980 962 € | 40 279 930 € | 42 176 050 € | 33 092 225 € | 23 817 099 € | 6 664 154 € | 24 213 014 € |
| EBITDA | 122 018 911 € | 93 958 161 € | 73 514 958 € | 49 917 572 € | 72 285 987 € | 76 551 508 € | 59 326 027 € | 43 432 145 € | 12 283 398 € | 48 384 690 € |
| Net margin | 25.2% | 22.1% | 20.4% | 17.1% | 21.8% | 22.3% | 20.4% | 20.9% | 18.8% | 17.1% |
In 2024, LABORATOIRE UNITHER achieves revenue of 287.9 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +9.3%. Vs 2023, growth of +21% (238.8 M€ -> 287.9 M€). After deducting consumption (58.8 M€), gross margin stands at 229.1 M€, i.e. a rate of 80%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 122.0 M€, representing 42.4% of revenue. Positive scissor effect: EBITDA margin improves by +3.0 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 72.6 M€, i.e. 25.2% of revenue. This profit can be retained or distributed to shareholders.
287 947 277 €
229 142 920 €
122 018 911 €
108 225 805 €
72 633 389 €
42.4%
The debt ratio (= Financial debt / Equity x 100) stands at 15%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 65%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.3 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 30.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
15.314%
64.751%
30.547%
0.315
54.9%
In 2024, the debt ratio of LABORATOIRE UNITHER (15.31) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of LABORATOIRE UNITHER (64.8%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of LABORATOIRE UNITHER (0.32) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 168.09. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 1.0x. Coverage is limited: any activity downturn would jeopardize interest payments.
168.093
1.011
In 2024, the liquidity ratio of LABORATOIRE UNITHER (168.09) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of LABORATOIRE UNITHER (1.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 27 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 46 days. Favorable situation: supplier credit is longer than customer credit by 19 days. Inventory turnover is 58 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 16 days of revenue, i.e. 12.7 M€ to permanently finance. Over 2016-2024, WCR increased by +397%, requiring additional financing.
12 718 631 €
27 j
46 j
58 j
16 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 14 491 760€ to 44 542 005€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare LABORATOIRE UNITHER with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of LABORATOIRE UNITHER in 2024 is 287.9 M€.
Yes, LABORATOIRE UNITHER generated a net profit of 72.6 M€ in 2024.
The headquarters of LABORATOIRE UNITHER is located in AMIENS (80080), in the department Somme.
The tax return of LABORATOIRE UNITHER is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
LABORATOIRE UNITHER operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.